Peregrine to initiate bavituximab combination therapy trial in India

By E. Janene Geiss

Philadelphia, Sept. 11 - Peregrine Pharmaceuticals, Inc. said Monday that it is completing plans to begin a clinical trial in India of bavituximab in combination with chemotherapy.

The trial is primarily designed to test the safety and tolerability of bavituximab with several standard chemotherapy regimens commonly used for treating major cancer types, including breast, lung and pancreatic cancer, according to a company news release.

The Tustin, Calif., biopharmaceutical company said it is collaborating with an experienced Indian contract research organization with recent success in managing a registration clinical trial for a novel monoclonal antibody therapeutic.

Peregrine said it expects that results from this study, along with data from its ongoing U.S. phase 1 cancer trial, will help support advancing bavituximab into phase 2 cancer trials in 2007.

Bavituximab is being studied in phase l clinical trials in the United States for the treatment of solid tumors and chronic hepatitis C infection.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.